Blood Biomarker in Early Parkinson's Disease
- Conditions
- Parkinson Disease
- Registration Number
- NCT03384797
- Lead Sponsor
- Duke University
- Brief Summary
Currently, there are no cures or disease modifying therapies for Parkinson's disease (PD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for PD. Several detection parameters will be assessed through enrollment of Parkinson's patients and age matched healthy volunteers over 50 years of age to learn more about the analytical process and biological variability.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 65
Not provided
Parkinson's Disease Patients:
- Known additional neurological disease
- Clinical trial intervention within the last 6 months
Healthy Control Participants:
- Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
- Clinical trial intervention within the last 6 months
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biological marker of Parkinson's disease Day 1 Test for biological marker of Parkinson's disease, mtDNA damage
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Duke University Medical Facility
🇺🇸Durham, North Carolina, United States